---
title: "Giant Biogene Holding Co., Ltd. (02367.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02367.HK.md"
symbol: "02367.HK"
name: "Giant Biogene Holding Co., Ltd."
industry: "Personal Care Products"
---

# Giant Biogene Holding Co., Ltd. (02367.HK)

| Item | Detail |
|------|--------|
| Industry | Personal Care Products |
| Location | HK Market |
| Website | [www.xajuzi.com](https://www.xajuzi.com) |

## Company Profile

Giant Biogene Holding Co., Ltd., an investment holding company, designs, develops, manufactures, and sells skin treatment products with recombinant collagen in the People’s Republic of China. It also develops and manufactures rare ginsenosides technology-based functional food products; and offers me...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:11.000Z

**Overall: B (0.21)**

**Industry**: Personal Care Products

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 20 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 37.26% |  |
| Net Profit YoY | 28.09% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.64 |  |
| Dividend Ratio | 3.81% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 36.67B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 6.63B |  |


**Multi Score**: B

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 29.86% | A |
| Profit Margin | 37.00% | A |
| Gross Margin | 81.68% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 37.26% | A |
| Net Profit YoY | 28.09% | B |
| Total Assets YoY | 47.75% | A |
| Net Assets YoY | 56.65% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 270.25% | C |
| OCF YoY | 37.26% | A |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.64 | B |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 18.58% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Giant Biogene Holding Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "29.86%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "37.00%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "81.68%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "37.26%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "28.09%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "47.75%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "56.65%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "270.25%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "37.26%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.64",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "18.58%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | MAO GEPING (HK.1318) | A | A | A | A | B | A |
| 02 | GIANT BIOGENE (HK.2367) | A | A | B | A | B | B |
| 03 | CHICMAX (HK.2145) | A | B | A | B | B | B |
| 04 | SOFTCARE (HK.2698) | A | B | A | C | C | B |
| 05 | MING FAI INT'L (HK.3828) | B | C | A | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.79 | 6/23 | 33.50 | 26.66 | 15.63 |
| PB | 3.64 | 18/23 | 9.73 | 7.30 | 3.85 |
| PS (TTM) | 5.47 | 20/23 | 12.67 | 9.93 | 5.78 |
| Dividend Yield | 3.81% | 8/23 | 3.61% | 2.31% | 1.39% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-16T16:00:00.000Z

Total Analysts: **20**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 15 | 75% |
| Overweight | 3 | 15% |
| Hold | 2 | 10% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 34.24 |
| Highest Target | 85.00 |
| Lowest Target | 35.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/02367.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02367.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02367.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.